Similarly, another study assessed the efficacy and safety of pembrolizumab in patients with metastatic NSCLC who have received prior first-line immunotherapy (PD-1/PD-L1 inhibitor alone or in combination with platinum-doublet chemotherapy). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.